Literature DB >> 31057740

Preparation and evaluation of 99mTc-labeled porphyrin complexes prepared using PNP and HYNIC cores: studying the effects of core selection on pharmacokinetics and tumor uptake in a mouse model.

Mohini Guleria1, Tapas Das1,2, Kusum Vats1, Jeyachitra Amirdhanayagam1, Anupam Mathur3, Haladhar D Sarma4, Ashutosh Dash1,2.   

Abstract

Porphyrins are tetrapyrrolic macrocyclic ligands known for their affinity towards neoplastic tissues and once radiolabeled with a suitable diagnostic radioisotope could potentially be used for the imaging of tumorous lesions. In the present study, an unsymmetrically substituted porphyrin derivative namely 5-(p-amino-propyloxyphenyl)-10,15,20-tris(carboxymethyleneoxyphenyl)-porphyrin was synthesized and modified further to enable radiolabeling with 99mTc using two different 99mTc-cores viz. 99mTc-HYNIC (hydrazino nicotinic acid) and 99mTc(N)PNP2 (PNP2 = bis-[(2-dimethylphosphino)ethyl]-methoxy-ethylamine) in order to study the effect of employing different 99mTc-cores on tumor affinity and pharmacokinetic behavior of the resultant 99mTc-labeled porphyrin complexes. 99mTc-Porphyrin complexes were characterized by reversed phase HPLC studies and could be prepared with >95% radiochemical purity under optimized radiolabeling conditions. Both 99mTc-complexes were found to be adequately stable in human blood serum till 3 h post-preparation. Bio-distribution studies, carried out in Swiss mice bearing fibrosarcoma tumors, revealed relatively higher tumor uptake for the 99mTc-HYNIC-porphyrin complex (3.95 ± 1.42 and 3.28 ± 0.27% IA per g) compared to that exhibited by the 99mTc(N)PNP-DTC-porphyrin complex (1.52 ± 0.53 and 1.56 ± 0.10% IA per g) at 1.5 and 3 h post-administration, although the former complex exhibited comparatively lower lipophilicity in the octanol-water system. Higher uptake and longer retention in the blood were observed for the 99mTc-HYNIC-porphyrin complex (6.63 ± 0.75 and 4.36 ± 0.25% IA per g) compared to that exhibited by the 99mTc(N)PNP-DTC-porphyrin complex (2.41 ± 0.54 and 2.30 ± 0.16% IA per g) at both 1.5 and 3 h post-administration. However, relatively lower liver uptake was observed for the former complex (19.26 ± 3.48 and 18.45 ± 1.05% IA per g) than that exhibited by the latter one (39.37 ± 3.88 and 34.15 ± 8.25% IA per g) at both 1.5 and 3 h post-administration. This study indicates that the in vivo behavior exhibited by the 99mTc-labeled porphyrins not only depends on their lipophilicity/hydrophilicity but is also governed by the Tc-cores employed for radiolabeling.

Entities:  

Year:  2019        PMID: 31057740      PMCID: PMC6482877          DOI: 10.1039/c8md00559a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  25 in total

1.  Biodistribution and pharmacokinetic studies of a porphyrin dimer photosensitizer (Oxdime) by fluorescence imaging and spectroscopy in mice bearing xenograft tumors.

Authors:  Mamta Khurana; Sébastien Ulrich; Anthony Kim; Yumi Moriyama; George Netchev; Margarete K Akens; Harry L Anderson; Brian C Wilson
Journal:  Photochem Photobiol       Date:  2012-07-26       Impact factor: 3.421

Review 2.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

Review 3.  Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress.

Authors:  M G Vicente
Journal:  Curr Med Chem Anticancer Agents       Date:  2001-08

4.  109Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a potential agent for targeted tumor therapy.

Authors:  Tapas Das; Sudipta Chakraborty; H D Sarma; Sharmila Banerjee
Journal:  Curr Radiopharm       Date:  2012-10

5.  Biologic evaluation of a novel 188Re-labeled porphyrin in mice tumor model.

Authors:  Haladhar D Sarma; Tapas Das; Sharmila Banerjee; Meera Venkatesh; Pandit B Vidyasagar; Kaushala P Mishra
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

6.  Significantly increased lesion size by using the near-infrared photosensitizer 5,10,15,20-tetrakis (m-hydroxyphenyl)bacteriochlorin in interstitial photodynamic therapy of normal rat liver tissue.

Authors:  J P Rovers; M L de Jode; M F Grahn
Journal:  Lasers Surg Med       Date:  2000       Impact factor: 4.025

7.  Chemistry of the strong electrophilic metal fragment [(99)Tc(N)(PXP)](2+) (PXP = diphosphine ligand). A novel tool for the selective labeling of small molecules.

Authors:  Cristina Bolzati; Alessandra Boschi; Licia Uccelli; Francesco Tisato; Fiorenzo Refosco; Aldo Cagnolini; Adriano Duatti; Sushumna Prakash; Giuliano Bandoli; Andrea Vittadini
Journal:  J Am Chem Soc       Date:  2002-09-25       Impact factor: 15.419

8.  Comparison of reversed phase and reversed phase ion pair high performance liquid chromatography for analysis of TcO and TcN complexes of L,L-ethylene dicysteine di-ethylester and its acid analogues.

Authors:  K O Mang'era; E Bellande; R Pasqualini; A Verbruggen
Journal:  J Pharm Biomed Anal       Date:  1996-06       Impact factor: 3.935

Review 9.  Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential.

Authors:  Ines Batinić-Haberle; Júlio S Rebouças; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

Review 10.  On the mechanism of the tumour-localising effect in photodynamic therapy.

Authors:  M R Hamblin; E L Newman
Journal:  J Photochem Photobiol B       Date:  1994-04       Impact factor: 6.252

View more
  1 in total

Review 1.  Advantages of combined photodynamic therapy in the treatment of oncological diseases.

Authors:  Mikhail Grin; Nikita Suvorov; Petr Ostroverkhov; Viktor Pogorilyy; Nikita Kirin; Alexander Popov; Anna Sazonova; Elena Filonenko
Journal:  Biophys Rev       Date:  2022-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.